Top Page
ImExHS Limited
(Sydney:IME)
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
ImExHS Limited Business Overview & Revenue Model
ImExHS Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.57M | 19.67M | 17.12M | 13.37M | 10.91M |
| Gross Profit | 11.03M | 3.50M | 3.52M | 3.35M | 2.70M |
| EBITDA | -908.00K | -1.26M | -749.00K | -3.00M | -1.30M |
| Net Income | -2.63M | -4.19M | -3.04M | -4.70M | -3.62M |
Balance Sheet | |||||
| Total Assets | 21.81M | 22.65M | 20.99M | 25.01M | 20.80M |
| Cash, Cash Equivalents and Short-Term Investments | 2.07M | 2.36M | 1.91M | 4.19M | 10.80M |
| Total Debt | 1.19M | 1.29M | 1.12M | 2.40M | 1.70M |
| Total Liabilities | 7.33M | 6.67M | 5.09M | 8.36M | 5.27M |
| Stockholders Equity | 14.47M | 15.98M | 15.90M | 16.65M | 15.54M |
Cash Flow | |||||
| Free Cash Flow | -1.69M | 414.59K | -4.23M | -5.53M | -3.65M |
| Operating Cash Flow | -634.68K | 2.61M | -2.20M | -2.97M | -1.47M |
| Investing Cash Flow | -765.91K | -2.13M | -2.22M | -3.39M | -2.19M |
| Financing Cash Flow | 1.18M | -98.61K | 2.25M | -161.78K | 7.40M |
ImExHS Limited Technical Analysis
ImExHS Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | 16.01M | -10.00 | 0.00% | ― | 28.91% | -1050.00% | |
56 Neutral | 25.93M | -0.44 | 0.00% | ― | -48.41% | -6520.00% | |
55 Neutral | 107.25M | -11.36 | 0.00% | ― | 25.98% | 21.43% | |
54 Neutral | AU$13.75M | ― | -27.84% | ― | 6.77% | -8.45% | |
52 Neutral | 61.02M | -10.38 | 0.00% | ― | 3.61% | -16.48% | |
40 Underperform | 87.52M | -12.78 | 0.00% | ― | 0.00% | 0.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
ImExHS Limited Corporate Events
ImExHS Limited has announced the issuance of 267,424 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move, part of an employee incentive scheme, is expected to enhance the company’s operational flexibility and could potentially strengthen its market position by aligning employee interests with corporate growth objectives.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest, specifically involving Carlos Jaime Palacio. The update reveals that Mr. Palacio has acquired 53,485 fully paid ordinary shares in lieu of director fees for the quarters ending June and September 2025, increasing his direct holdings to 325,442 shares. This change reflects the company’s practice of compensating directors with shares, which may align their interests more closely with those of shareholders.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest notice, specifically involving Douglas Lingard. On September 8, 2025, Mr. Lingard acquired 53,485 fully paid ordinary shares directly, in lieu of non-executive director fees for the quarters ending June 30 and September 30, 2025. This acquisition reflects a strategic decision to align director compensation with company performance, potentially impacting investor perceptions and stakeholder confidence in the company’s governance practices.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest notice, specifically regarding Damian Banks. The change involves the acquisition of 53,485 fully paid ordinary shares by Damian Banks, issued in lieu of non-executive director fees for the quarters ending June and September 2025. This adjustment reflects the company’s ongoing management and allocation of director compensation, potentially impacting shareholder perceptions and the company’s governance practices.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has announced a change in the director’s interest, specifically regarding Douglas Flynn’s holdings. The company disclosed that Mr. Flynn acquired 106,969 fully paid ordinary shares in lieu of non-executive director fees for the quarters ending June and September 2025. This acquisition reflects a strategic decision to compensate directors with shares, potentially aligning their interests more closely with those of shareholders.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has released its 1H FY25 Results Investor Presentation, which will be discussed in a conference call with the investment community. This announcement highlights the company’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.35 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited reported its financial results for the first half of FY25, showing a 4% increase in revenue to $13.7 million and an 11% rise in annualized recurring revenue to $32.8 million. The company successfully launched its next-generation radiology platform, Aquila+, which has been well-received in the market, securing significant new contracts and expanding its partner program. Despite challenges such as currency fluctuations, IMEXHS maintained a positive underlying EBITDA and strengthened its balance sheet through capital raising. The company aims to accelerate sales and maintain margin discipline in the second half of the year.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited reported a slight decrease in revenues by 0.9% to $13.66 million for the half-year ending June 2025, alongside a significant increase in losses by 97.9% to $3 million. No dividends were declared during this period, and the financial statements received an unmodified opinion with an emphasis on going concern, highlighting challenges in the company’s financial performance.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited reported a Q2 FY25 revenue of $6.6 million, a slight decrease compared to the previous corresponding period, but an increase when excluding one-off sales. The company has announced a capital raising of $2.6 million to support growth and has expanded its partner program significantly, contributing to 40.6% of software revenue. Operationally, IMEXHS secured a major contract with Neurológico de México and continued the rollout of its AQUILA+ platform. Despite facing challenges in the Colombian healthcare market due to political reforms, the company has implemented strategies to manage working capital and improve profitability through cost reductions and technological advancements.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.75 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.